Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Ano de publicação
Tipo de documento
Assunto da revista
Intervalo de ano de publicação
1.
Vaccine ; 42(9): 2200-2211, 2024 Apr 02.
Artigo em Inglês | MEDLINE | ID: mdl-38350768

RESUMO

BACKGROUND: The Global COVID Vaccine Safety (GCoVS) Project, established in 2021 under the multinational Global Vaccine Data Network™ (GVDN®), facilitates comprehensive assessment of vaccine safety. This study aimed to evaluate the risk of adverse events of special interest (AESI) following COVID-19 vaccination from 10 sites across eight countries. METHODS: Using a common protocol, this observational cohort study compared observed with expected rates of 13 selected AESI across neurological, haematological, and cardiac outcomes. Expected rates were obtained by participating sites using pre-COVID-19 vaccination healthcare data stratified by age and sex. Observed rates were reported from the same healthcare datasets since COVID-19 vaccination program rollout. AESI occurring up to 42 days following vaccination with mRNA (BNT162b2 and mRNA-1273) and adenovirus-vector (ChAdOx1) vaccines were included in the primary analysis. Risks were assessed using observed versus expected (OE) ratios with 95 % confidence intervals. Prioritised potential safety signals were those with lower bound of the 95 % confidence interval (LBCI) greater than 1.5. RESULTS: Participants included 99,068,901 vaccinated individuals. In total, 183,559,462 doses of BNT162b2, 36,178,442 doses of mRNA-1273, and 23,093,399 doses of ChAdOx1 were administered across participating sites in the study period. Risk periods following homologous vaccination schedules contributed 23,168,335 person-years of follow-up. OE ratios with LBCI > 1.5 were observed for Guillain-Barré syndrome (2.49, 95 % CI: 2.15, 2.87) and cerebral venous sinus thrombosis (3.23, 95 % CI: 2.51, 4.09) following the first dose of ChAdOx1 vaccine. Acute disseminated encephalomyelitis showed an OE ratio of 3.78 (95 % CI: 1.52, 7.78) following the first dose of mRNA-1273 vaccine. The OE ratios for myocarditis and pericarditis following BNT162b2, mRNA-1273, and ChAdOx1 were significantly increased with LBCIs > 1.5. CONCLUSION: This multi-country analysis confirmed pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis. Other potential safety signals that require further investigation were identified.


Assuntos
COVID-19 , Síndrome de Guillain-Barré , Miocardite , Pericardite , Trombose dos Seios Intracranianos , Humanos , Vacina de mRNA-1273 contra 2019-nCoV , Vacina BNT162 , Estudos de Coortes , COVID-19/prevenção & controle , Vacinas contra COVID-19/efeitos adversos , Síndrome de Guillain-Barré/induzido quimicamente , Síndrome de Guillain-Barré/epidemiologia , Vacinas de mRNA , Vacinação/efeitos adversos , Masculino , Feminino
2.
Acta gastroenterol. latinoam ; 18(3): 215-7, jul.-set. 1988.
Artigo em Espanhol | LILACS | ID: lil-76622

RESUMO

The intraabdominal punction tecnique is harmless and causes very little disturvance to the patient. It gives the pathologist enough adequate material for his diagnosis. The abdominal punction using a chiba needle also permits one to evaluate the extension of the illness. Medical literature only states a few complications such as peritonitis in pancreatic punctions. The diagnosis of no-Hodking Lymphoma based on the monomorphism and the sizes and the nuclear clefts, does no ofter many difficulties, nervertheless, the obtained material does not allow one to differenciate between nodular and diffuse lymphoma and therapeutic datum. It this sense, Histology surpasses Cytology


Assuntos
Pessoa de Meia-Idade , Humanos , Masculino , Neoplasias Abdominais/diagnóstico , Linfoma não Hodgkin/diagnóstico , Punções , Ultrassonografia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA